Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents

Hetrick, Sarah; Merry, Sally; McKenzie, Joanne E.; Sindahl, Per; Proctor, Michelle

doi:10.1002/14651858.cd004851.pub2

Cited by 133 publications

(121 citation statements)

References 104 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…A systemic review of published and unpublished randomised controlled trials comparing the efficacy and adverse events of SSRIs with placebo suggested that only fluoxetine therapy is effective. However the adverse events and risk of suicidal ideation and behaviour were increased the SSRIs-treated group (Hetrick et al, 2007). The meta-analyses of Whittington et al (2004) and Usala et al (2008) also supported the previous review.…”

Section: Selective Serotonin Reuptake Inhibitorssupporting

confidence: 82%

Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder

Maneeton¹

2012

Mental Illnesses - Evaluation, Treatments and Implications

View full text Add to dashboard Cite

Section: Selective Serotonin Reuptake Inhibitorssupporting

confidence: 82%

Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder

Maneeton¹

2012

Mental Illnesses - Evaluation, Treatments and Implications

View full text Add to dashboard Cite

“…It should be mentioned that the use of SSRIs in children and adolescents has been debated recently, and there have been warnings against their use due to concerns about increased risk of suicidal ideation and behaviour (Hetrick et al 2007;Scahill et al 2005). In 2003, the FDA issued a public health warning stating that preliminary evidence showed SSRIs and related antidepressants might be associated with excess reports of suicidality.…”

Section: Treating Children and Adolescentsmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

“…В аспекте рассматриваемой в настоящем обзоре про-блемы особый интерес представляют антидепрессанты, являющиеся одними из основных средств при фармако-логическом лечении депрессии и расстройств, связанных с тревогой, и при суицидальном поведении. В этом случае ключевую роль играют антидепрессанты из группы селек-тивных ингибиторов обратного захвата серотонина (СИОЗС), которые являются препаратами первой линии выбора [35][36][37].…”

Section: профилактика и лечениеunclassified

Childhood maltreatment and its impact on the mental health

Sivolap

Portnova

2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents

Cited by 133 publications

References 104 publications

Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder

Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Childhood maltreatment and its impact on the mental health

Contact Info

Product

Resources

About